Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Brims, C. Fehrenbach, A. Chauhan (Portsmouth, United Kingdom). Tiotropium in severe asthma: an open label review of clinical efficacy. Eur Respir J 2007; 30: Suppl. 51, 3616

Member's Comments

No comment yet.

Related content which might interest you: Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Erdosteine is effective as a treatment for acute exacerbation of COPD: a systematic review of clinical trials Source: International Congress 2017 – COPD management Year: 2017 Safety of formoterol in asthma clinical trials: an update Source: Eur Respir J 2014; 43: 103-114 Year: 2004 The utility of tiotropium among patients with chronic obstructive pulmonary disease (COPD): An updated meta-analysis of randomized controlled trials Source: Annual Congress 2013 –Quality of diagnosis and assessment in primary care Year: 2013 Clinical and functional effectiveness of roflumilast in severe COPD patients Source: Annual Congress 2013 –Modern approach to various clinical settings Year: 2013 The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis Source: International Congress 2019 – Clinical and translational studies of bronchiectasis and non-TB mycobacterial infection Year: 2019 Efficacy of fenspiride in infants with bronchiolitis: a preliminary open label clinical trial Source: Eur Respir J 2004; 24: Suppl. 48, 24s Year: 2004 Late Breaking Abstract - Can a self-management plan, which includes a four-fold increase in inhaled corticosteroid dose, reduce severe asthma exacerbations: a randomised, pragmatic trial. Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017 Efficacy and safety of erdosteine in COPD: Results of a 12-month prospective, multinational study Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Tiotropium use in COPD: association with clinical diagnosis assignment Source: Annual Congress 2007 - Epidemiology of COPD Year: 2007 Tiotropium reduces the risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Long-acting β-agonists: a review of formoterol safety data from asthma clinical trials Source: Eur Respir J 2009; 33: 21-32 Year: 2009 Clinical phenotypes of asthmatics who require long-term use of tiotropium for asthma control: a real-world study Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability Source: International Congress 2014 – Markers Year: 2014 Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Does the use of inhaled corticosteroids in asthma benefit lung function in the long-term? A systematic review and meta-analysis Source: Eur Respir Rev, 30 (159) 200185; 10.1183/16000617.0185-2020 Year: 2021 QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Assessment of efficacy and tolerability of roflumilast add-on to LABA/LAMA/ICS in the treatment of COPD in Indian patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016